Citius Oncology (CTOR) Preferred Stock Liabilities (2022 - 2024)

Citius Oncology's Preferred Stock Liabilities history runs 3 years deep, the most recent figure standing at $49.2 million for Q2 2024.

• In Q2 2024, Preferred Stock Liabilities fell 29.16% year-over-year to $49.2 million; the TTM figure through Jun 2024 stood at $49.2 million (down 29.16% YoY), while the FY2023 annual figure was $72.6 million, up 7.01% from the prior year.
• Preferred Stock Liabilities was $49.2 million for Q2 2024 at Citius Oncology, up from $48.3 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $72.6 million in Q4 2023 to a low of $48.3 million in Q1 2024.
• Historically, Preferred Stock Liabilities has averaged $63.8 million across 3 years, with a median of $68.6 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Preferred Stock Liabilities grew 7.01% in 2023, then fell 29.54% in 2024.
• A 3-year view of Preferred Stock Liabilities shows it stood at $67.8 million in 2022, then grew by 7.01% to $72.6 million in 2023, then plunged by 32.26% to $49.2 million in 2024.
• The last three Preferred Stock Liabilities figures came in at $49.2 million (Q2 2024), $48.3 million (Q1 2024), and $72.6 million (Q4 2023), per Business Quant data.